An innovative sealed shoe to off-load and heal diabetic forefoot ulcers – a feasibility study

Gustav Jarl* and Roy Tranberg*

*Department of Prosthetics and Orthotics, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; †University Health Care Research Center, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; ‡Department of Orthopaedics, Institute of Clinical Sciences, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden

**ABSTRACT**

**Background:** Non-removable knee-high devices are the gold standard to treat diabetic foot ulcers located on the plantar forefoot, but they immobilize the ankle, which restricts daily life activities and has negative effects on joint functioning.

**Objective:** To investigate the feasibility of sealing a therapeutic shoe to off-load and heal diabetic forefoot ulcers.

**Design:** A case series of seven men with type 2 diabetes and a metatarsal head ulcer were prescribed therapeutic shoes and custom-made insoles. The shoe was sealed with a plastic band. Off-loading was assessed with the F-scan pressure measurement system. Adherence to wearing the shoe was assessed with a temperature sensor and by documenting the status of the seal.

**Results:** The off-loading was effective and all ulcers healed. Median time to healing was 56 days (range 8–160). Complications were secondary ulcer (n = 1) and plantar hematoma (n = 1). Five of seven participants did not disturb the seal.

**Conclusions:** Sealing a therapeutic shoe is a feasible way to off-load and heal forefoot ulcers. A controlled trial is needed to compare the effectiveness and safety of a sealed shoe to other non-removable devices.

**Background**

Approximately 20% of diabetic foot ulcers are located on the plantar forefoot [1,2]. Total contact casts (TCCs) and cast walkers rendered irremovable are the gold standard to off-load and heal these ulcers [3–5], but they immobilize the ankle, which restricts daily life activities [3] and has negative effects on joint functioning [6]. A possible alternative would be an ankle-high device rendered irremovable, and a case study reported successful result with using a plaster shoe instead of a knee-high TCC [7]. To the authors’ knowledge, this idea has not been extended to therapeutic shoes. The study aim was to investigate the feasibility of using a therapeutic shoe, rendered irremovable, to off-load and heal forefoot ulcers.

**Design**

The study was a case series approved by the Regional Ethics Committee Review Board of Uppsala. Inclusion criteria were diabetes mellitus and a metatarsal head (MTH) ulcer. Exclusion criteria were toe pressure <40 mmHg, active Charcot foot, and deformity that prevented use of off-the-shelf therapeutic shoes.

Presence of neuropathy was investigated with a 10 g monofilament under the first toe and the first and fifth MTH, and with a tuning fork (128 Hz) on the dorsal side of the first toe, following the guidelines of the International Working Group on the Diabetic Foot [8]. Passive dorsal flexion range of motion was investigated in the ankle (with knee extended) and first toe on the ulcerated foot. Participants had their toe pressure measured and received extra-depth therapeutic roller shoes. One author (GJ) made casts of the participants’ feet and produced custom-made insoles of 14 mm ethylene–vinyl acetate (two layers with a hardness of 50 and 20 Shore) with 3 mm microcellular urethane glued on the top surface. A sensor (Orthotimer, Balingen, Germany) measuring the temperature every 15 min was used to measure the temperature every 15 min was placed under the urethane layer. The insoles were ground to the shoes leaving 10 mm of material under the heel and 15 mm under the MTHs. The ulcer was off-loaded by grinding the insole from the underside on the location of the ulcer until the urethane layer was exposed. An F-scan system [9] was used to measure plantar pressures as the person walked three times, 8 s per time, at a self-selected speed on a level surface. The insoles were then adjusted as necessary and the pressure measurement repeated to ensure that the ulcer was off-loaded and that there were no excessive pressures.
Participants broke in the shoes by wearing them for 7 days and one night. After this, the shoe on the ulcerated foot was sealed with a plastic band (Figure 1). Participants were instructed to break the seal and remove the shoe only if they experienced any sign of deterioration of the foot or general condition, or if something had fallen into the shoe. Thus, participants wore the shoe day and night and were free to walk as much as they desired during the treatment period. Shoe covers were used when sleeping and showering. A primary care nurse re-dressed the ulcer (typically 1–2 times/week) and documented whether the seal was broken or not, as well as complications and complaints before sealing the shoe again. Every 14 days, a podiatrist revised the ulcer using sharp debridement. Healing was defined as the date when the ulcer was completely epithelized if it was still epithelized 14 days later [10].

After healing, participants filled in a questionnaire about advantages and disadvantages with a sealed shoe compared with removable shoes and TCCs.

**Results**

Seven men with type 2 diabetes for >10 years participated (Table 1). No participant could feel the monofilament or tuning fork. The ulcers had Wagner grade 1 and 2. Median ulcer duration was 1.0 years and median ulcer size (longest diameter multiplied by longest perpendicular diameter) was 0.5 cm².

![Figure 1. The therapeutic shoe was sealed by threading a plastic band (Brace-lok, DJO Nordic, Malmö, Sweden) through two holes; one on each side of the shoe’s opening.](image)

| Sex          | Age, years | Ankle dorsal flexion ROM*, degrees | First toe dorsal flexion ROM*, degrees | Toe pressure*, mmHg | Ulcer location | Wagner grade | Ulcer size**, cm² | Ulcer duration, years | Time to healing, days |
|--------------|------------|-----------------------------------|----------------------------------------|---------------------|----------------|--------------|-------------------|-----------------------|----------------------|
| Men (n=7)    | 6 (3–10)   | 40 (30–70)                        | 112 MTH                                 | 1 (n=4)             | Grade 1 (n=4) | 0.5          | 1.0               | 56                    | 38–60                |
| Women (n=0)  | 40–80      | 55–165                            | MTH 5 (n=1)                            |                     |                |              |                  |                       |                      |

Continuous variables are medians (min–max). *On the ulcerated foot. **Calculated as longest diameter multiplied by longest perpendicular diameter. MTH: metatarsal head. ROM: range of motion.
All ulcers healed. Time from sealing of the shoe to healing was 8–66 days for six ulcers and 160 days for one ulcer, median 56 days. The most frequent complications were considered as minor, such as redness of the skin. One participant did, however, develop a secondary ulcer on the dorsum of the foot. After this ulcer had healed, he rejoined the study, now with a seal that allowed adjustment of the Velcro to accommodate the varying edema. Another participant developed a plantar hematoma, but it healed without ulceration.

The median peak pressure on the ulcer was 116 kPa (62–192 kPa) when walking with the shoe. Five participants respected the seal and only removed the shoe on legitimate occasions such as medical examinations. One participant broke the seal and removed the shoe at night, but was very adherent in the daytime. Another participant removed the shoe on a few occasions without breaking the seal. The temperature data were useful for assessing adherence, but in some cases equivocal: a temperature drop could reflect either that the participant removed the shoe or went outdoors in cold weather. All participants had previously used removable therapeutic shoes, and reported advantages with a sealed shoe were reasonably quick healing (n = 1) and not being tempted to walk without the shoe (n = 1). Disadvantages were that the shoe was hot/sweaty (n = 1) and caused difficulties in dressing (n = 5), showering (n = 1) and sleeping (n = 1). Four participants had previously used a TCC, and reported that advantages with a sealed shoe were being able to work and move around almost normally without crutches (n = 1) and not having to change casts (n = 1). No disadvantages were reported.

**Discussion**

This study supports the feasibility of sealing a therapeutic shoe to off-load and heal diabetic forefoot ulcers. Guidelines [3,11,12] recommend non-removable knee-high devices to heal forefoot ulcers because of their off-loading capacity and ‘forced adherence’. Our pressure measurements demonstrated that a therapeutic shoe with an optimized insole can effectively off-load at least small forefoot ulcers. However, one plantar hematoma developed, which indicated that shoes might not be feasible for off-loading all ulcers. Although sealing did not result in 100% adherence, adherence reached levels that allowed most ulcers to heal within a reasonably short time. Still, we cannot exclude that adherence partly improved because participants knew that the temperature sensor would register any removal of the shoe.

Guidelines [3,11] recommend therapeutic shoes to prevent reulceration after healing. However, if reulceration occurs after changing from a non-removable knee-high device to shoes, the person might attribute the new ulcer to the shoes per se rather than to low adherence to wearing them. In contrast, if reulceration occurs after removing a seal from the shoe this can serve to educate the patient of the importance of adherence. Hopefully, this can empower patients to break the vicious cycle of reulceration, effective treatment, and non-effective prevention.

One participant developed a secondary ulcer and another removed the shoe at nighttime, in both cases because edema had caused pressure on the foot. Thus, special caution should be taken if edema is present. Notably, the participant who developed the ulcer had previously developed an ulcer in the same location when wearing a TCC.

This study has some limitations. First, no strict criterion was used to decide whether the ulcers were adequately off-loaded or not. Second, the sample was small and included men with type 2 diabetes only. Acknowledging these limitations, sealed shoes are an interesting avenue for future research as they include some of the advantages of non-removable knee-high devices and avoid some of the disadvantages that limit their clinical use [13–15]. For example, a sealed shoe does not immobilize the ankle joint. In addition, a sealed shoe might be a more attractive alternative in low- and middle-income countries as no special technical expertise is needed for application of a TCC. Furthermore, the same device can be used to both prevent and heal ulcers, thus limiting costs. To investigate the effectiveness and safety of this concept with other non-removable devices, a larger randomized controlled study is needed.

**Acknowledgements**

The authors thank Carlos Martin de los Santos Diaz and Anne-Christine Hjerpe, podiatrists at Örebro University Hospital, and the nurses in primary care for collecting data.

**Disclosure statement**

No potential conflict of interest was reported by the authors.

**Funding**

This work was supported by the Region Örebro County; the Promobilia Foundation [grant number OLL-459501];

**Notes on contributors**

**Gustav Jarl**, Certified Prosthetist and Orthotist, PhD, has been working at the Department of Prosthetics and Orthotics in Örebro, Sweden, since 2005. His main research interest is diabetic foot complications with special focus on off-loading and adherence.

**Roy Tranberg**, Certified Prosthetist and Orthotist, PhD, has been working at the Lundberg Laboratory for Orthopaedic Research at the Sahlgrenska University Hospital since 1997. His main research interest is in gait disorders with special focus on patients with diabetes.
The study was conducted at Örebro University Hospital, Örebro, Sweden.

References

[1] Prompers L, Huijberts M, Apelqvist J, et al. High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. Diabetologia. 2007 Jan;50(1):18–25. PubMed PMID: 17093942. DOI:10.1007/s00125-006-0491-1.

[2] Örneholm H, Apelqvist J, Larsson J, et al. High probability of healing without amputation of plantar forefoot ulcers in patients with diabetes. Wound Repair Regen. 2015 Nov 12;23(6):922–931. PubMed PMID: 26084518. DOI:10.1111/wrr.12328.

[3] Bus SA, Armstrong DG, Van Deursen RW, et al. IWGDF guidance on footwear and offloading interventions to prevent and heal foot ulcers in patients with diabetes. Diabetes Metab Res Rev. 2016 Jan;32(Suppl 1):25–36. PubMed PMID: 26813614. DOI:10.1002/dmrr.2697.

[4] Elraiyah T, Prutsky G, Domecq JP, et al. A systematic review and meta-analysis of off-loading methods for diabetic foot ulcers. J Vasc Surg. 2016 Feb;63(2 Suppl):59S–68S. PubMed PMID: 26804367. DOI:10.1016/j.jvs.2015.10.003.

[5] Bus SA, Van Deursen RW, Armstrong DG, et al. Footwear and offloading interventions to prevent and heal foot ulcers and reduce plantar pressure in patients with diabetes: a systematic review. Diabetes Metab Res Rev. 2016 Jan;32(Suppl 1):99–118. PubMed PMID: 26342178. DOI:10.1002/dmrr.2702.

[6] Sinacore DR, Mueller MJ. Off-loading for diabetic foot disease. In: Bowker JH, Pfeifer MA, editors. Levin and Neal’s the diabetic foot. Philadelphia: Mosby/Elsevier; 2008. p. 287–304.

[7] Diamond JE, Sinacore DR, Mueller MJ. Molded double-rocker plaster shoe for healing a diabetic plantar ulcer. A case report. Phys Ther. 1987 Oct;67(10):1550–1552. PubMed PMID: 3659139.

[8] Bakker K, Apelqvist J, Schaper NC. Practical guidelines on the management and prevention of the diabetic foot 2011. Diabetes Metab Res Rev. 2012 Feb;28(Suppl 1):225–231. PubMed PMID: 22271742; eng. DOI:10.1002/dmrr.2253.

[9] Price CPD, Nester C. Validity and repeatability of three in-shoe pressure measurement systems. Gait Posture. 2016;46:69–74. DOI:10.1016/j.gaitpost.2016.01.026.

[10] Food and Drug Administration. Guidance for industry: chronic cutaneous ulcer and burn wounds - developing products for treatment: U.S. Department of Health and Human Services Food and Drug Administration. 2006 [cited 2016 December 21] Available from: http://www.fda.gov/downloads/Drugs/guidancecomplianceregulatoryinformation/guidances/ucm071324.pdf.

[11] Hingorani A, LaMuraglia GM, Henke P, et al. The management of diabetic foot: A clinical practice guideline by the society for vascular surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine. J Vasc Surg. 2016 Feb;63(2 Suppl):3s–21s. PubMed PMID: 26804367. DOI:10.1016/j.jvs.2015.10.003.

[12] Snyder R, Frykberg R, Rogers L, et al. The management of diabetic foot ulcers through optimal off-loading: building consensus guidelines and practical recommendations to improve outcomes. J Am Podiatr Med Assoc. 2014 Nov;104(6):555–567. PubMed PMID: 25514266. DOI:10.7547/8750-7315-104.6.555.

[13] Wu SC, Jensen JL, Weber AK, et al. Use of pressure offloading devices in diabetic foot ulcers: do we practice what we preach? Diabetes Care. 2008 Nov;31(11):2118–2119. PubMed PMID: 18694976; PubMed Central PMCID: PMCPmc2571059. DOI:10.2337/dc08-0771.

[14] Fife CE, Carter MJ, Walker D, et al. Diabetic foot ulcer off-loading: the gap between evidence and practice. Data from the US wound registry. Adv Skin Wound Care. 2014 Jul;27(7):310–316. PubMed PMID: 24932951. DOI:10.1097/01.asw.0000450831.65667.89.

[15] Raspovic A, Landorf KB. A survey of offloading practices for diabetes-related plantar neuropathic foot ulcers. J Foot Ankle Res. 2014;7:35. PubMed PMID: 25694793; PubMed Central PMCID: PMCPmc4332025. DOI:10.1186/s13047-014-0035-8.